Specialty pharmaceutical company Mallinckrodt plc said it had a net loss of $352.4 million, or $4.14 a share, in its fiscal fourth quarter, compared with net income of $33.5 million, or 54 cents a share, in the-year earlier period, weighed down by special charges related to its medical imaging segment, restructuring and other items. On a non-GAAP basis, the company said per-share earnings came to $1.68, well ahead of the FactSet consensus of $1.36. Sales climbed 44.8% to $789.3 million, driven by the inclusion of some new products acquired earlier this year. The sales number also topped the FactSet consensus of $759 million. Shares were not yet active in premarket trade but are up a whopping 70% in the year so far, while the S&P 500 has gained 11%.
Copyright © 2014 MarketWatch, Inc.